公开(公告)号：US20250009720A1

公开(公告)日：2025-01-09

申请号：US18708616

申请日：2022-11-10

Applicant: APNIMED, INC. (DELAWARE)

Inventor： Lawrence G. MILLER ,  Ronald FARKAS ,  Luigi TARANTO-MONTEMURRO ,  David P. WHITE

IPC: A61K31/433 ,  A61K31/138 ,  A61K31/496 ,  A61K31/5375

Abstract: Pharmaceutical compositions comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a carbonic anhydrase inhibitor (CAI), in the absence of an antimuscarinic agent, and methods of treating conditions associated with pharyngeal airway collapse are described herein.

公开(公告)号：US20240358709A1

公开(公告)日：2024-10-31

申请号：US18687660

申请日：2022-08-30

Applicant: APNIMED, INC. (DELAWARE)

Inventor： David P. WHITE ,  Luigi TARANTO-MONTEMURRO ,  Ronald FARKAS ,  Lawrence G. MILLER

IPC: A61K31/5375 ,  A61F5/56 ,  A61K31/138 ,  A61K31/216 ,  A61K31/437 ,  A61K31/496 ,  A61P11/04

CPC classification number: A61K31/5375 ,  A61F5/566 ,  A61K31/138 ,  A61K31/216 ,  A61K31/437 ,  A61K31/496 ,  A61P11/04

Abstract: Methods of treating pharyngeal airway collapse (e.g., sleep apnea) by administering a norepinephrine reuptake inhibitor (NRI) in combination with mandibular advancement device (MAD) therapy are described herein. The treatment may further comprise administration of a muscarinic receptor antagonist (MRA) and/or a hypnotic.

公开(公告)号：US20240189328A1

公开(公告)日：2024-06-13

申请号：US18286399

申请日：2022-04-15

Applicant: APNIMED, INC. (DELAWARE)

Inventor： Lawrence G. MILLER ,  Luigi TARANTO-MONTEMURRO ,  Ronald FARKAS ,  David P. WHITE

IPC: A61K31/00 ,  A61K31/138 ,  A61K31/216 ,  A61K31/433 ,  A61K31/5375 ,  A61P11/04

CPC classification number: A61K31/658 ,  A61K31/138 ,  A61K31/216 ,  A61K31/433 ,  A61K31/5375 ,  A61P11/04

Abstract: Pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI) and a cannabinoid and optionally a muscarinic receptor antagonist (MRA) and/or carbonic anhydrase inhibitor (CAI) and methods of treating sleep apnea are described herein.

公开(公告)号：US20250000823A1

公开(公告)日：2025-01-02

申请号：US18709055

申请日：2022-11-10

Applicant: APNIMED, INC. (DELAWARE)

Inventor： Luigi TARANTO-MONTEMURRO ,  David P. WHITE ,  Ronald FARKAS ,  Lawrence G. MILLER

IPC: A61K31/138 ,  A61K31/433 ,  A61P11/00

Abstract: Pharmaceutical compositions comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a carbonic anhydrase inhibitor (CAI) and methods of treating conditions associated with central hypoventilation are described herein.

公开(公告)号：US20240277719A1

公开(公告)日：2024-08-22

申请号：US18570673

申请日：2022-06-17

Applicant: APNIMED, INC. (DELAWARE)

Inventor： Luigi TARANTO-MONTEMURRO ,  Ronald FARKAS ,  David P. WHITE ,  Lawrence G. MILLER

IPC: A61K31/5375 ,  A61K9/00 ,  A61K31/216 ,  A61K31/496 ,  A61K31/5377 ,  A61P11/04

CPC classification number: A61K31/5375 ,  A61K9/0053 ,  A61K31/216 ,  A61K31/496 ,  A61K31/5377 ,  A61P11/04

Abstract: Methods of treating sleep apnea and snoring comprising administering a norepinephrine reuptake inhibitor, optionally in the absence of an antimuscarinic agent, and optionally as a monotherapy, are described herein. Pharmaceutical compositions comprising norepinephrine reuptake inhibitors, such as edivoxetine and viloxazine, are also described.